Analyst Ratings For China Biologic Products Holdings Inc (NASDAQ:CBPO)
Today, China Biologic Products Holdings Inc (NASDAQ:CBPO) stock was downgraded by Jefferies Financial Group from Hold to Underperform.
There are 2 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Buy Ratings on the stock.
The current consensus rating on China Biologic Products Holdings Inc (NASDAQ:CBPO) is Hold with a consensus target price of $89.6667 per share, a potential 8.25% upside.
Some recent analyst ratings include
- 3/11/2019-China Biologic Products Holdings Inc (NASDAQ:CBPO) gets downgraded to Underperform by Jefferies Financial Group
- 11/5/2018-China Biologic Products Holdings Inc (NASDAQ:CBPO) gets downgraded to Equal Weight by Morgan Stanley with a price target of $84.00
- 5/30/2017-China Biologic Products Holdings Inc (NASDAQ:CBPO) has coverage initiated with a Neutral ➝ Neutral rating
- On 5/9/2017 Zhijing Cbpo Liu, Insider, sold 7,500 with an average share price of $116.49 per share and the total transaction amounting to $873,675.00.
- On 3/2/2017 Sean Shao, Director, sold 20,000 with an average share price of $100.78 per share and the total transaction amounting to $2,015,600.00.
- On 3/1/2017 David Gao, CEO, sold 116,653 with an average share price of $100.63 per share and the total transaction amounting to $11,738,791.39.
- On 8/15/2016 Ming Yang, CFO, sold 21,092 with an average share price of $124.32 per share and the total transaction amounting to $2,622,157.44.
- On 8/15/2016 Wenfang Liu, Director, sold 2,900 with an average share price of $124.32 per share and the total transaction amounting to $360,528.00.
- On 8/15/2016 Zhijing Cbpo Liu, Insider, sold 1,968 with an average share price of $124.32 per share and the total transaction amounting to $244,661.76.
- On 6/8/2016 Wp X Biologics Llc, Director, sold 2,775,000 with an average share price of $111.00 per share and the total transaction amounting to $308,025,000.00.
About China Biologic Products Holdings Inc (NASDAQ:CBPO)
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
Recent Trading Activity for China Biologic Products Holdings Inc (NASDAQ:CBPO)
Shares of China Biologic Products Holdings Inc closed the previous trading session at 82,83 −0,78 0,93 % with 84.14 shares trading hands.
